--------------------------------------------------
Edison hatte 75 % Freefloat angegeben!
First Berlin 88,3 % Freefloat
Cosmo Pharmaceuticals 8.9%
TIAA-CREF 2.8%
--------------------------------------------------
Vertriebsbegin in Japan:
"PAION’s Japanese licensee, Mundipharma, has stated that it has recently launched the drug. The prevalence of SARSCoV-2 is far lower in Japan than in the US but in the 2019 annual report management gave conservative guidance (which we have adopted) of under €1m for combined 2020 royalties from both markets. "
--------------------------------------------------
Vertriebsvorteil bei Acacia:
"The rationale presented by Acacia for licensing in BYFAVO is that both products target the
same key physicians and that the value proposition underlying both products lies in
mobilising patients more quickly after a procedure."
--------------------------------------------------
US-Marktchancen
"Acacia’s management quantifies the US market opportunity for BARHEMSYS at USD460m annually
(assumes 15% market share of the PONV “rescue” market plus a 10% share of the combination prophylaxis market). This compares with our peak sales estimate for remimazolam in procedural sedation in the US of €203m. Revenues from both products will be required to justify the ca. 50 person marketing team Acacia is currently building for the US market."
--------------------------------------------------
hoffentlich dauert das nicht zuuuuu lange!
" ... to launch both BARHEMSYS and BYFAVO during the second half of this year but notes that marketing of BYFAVO in the US cannot commence until the Drug Enforcement Administration has determined scheduling of the drug under the Controlled Substances Act. We gather from Acacia’s conference call on 6 July that this may take between a few weeks and a few months "
Unser Kopf ist rund, damit das Denken die Richtung wechseln kann. Francis Picabia